# Dexamethasone

Source: https://onco.cc/drugs/dexamethasone/  
OnCo record `dexamethasone` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Dexamethasone is a long-acting glucocorticoid steroid that kills lymphoid cancer cells directly, which is why it sits in nearly every myeloma regimen and in childhood leukaemia and lymphoma protocols. It is also the standard drug for preventing chemotherapy sickness and for brain swelling and spinal cord compression; high blood sugar, insomnia, muscle wasting and infection follow prolonged use.

## Summary

Dexamethasone was approved in 1958 and is labelled for palliative management of leukaemias and lymphomas among dozens of inflammatory indications; in oncology it is the steroid of virtually every multiple myeloma regimen (with bortezomib, lenalidomide, daratumumab and the newer antibodies), of paediatric ALL induction where it replaced prednisone in several protocols, and of the R-CHOP-like and hyper-CVAD regimens. Hemady (20 mg tablets, 2019) is a US product labelled specifically for multiple myeloma, and Neofordex (40 mg tablets) was authorised in the EU in 2016 for the same disease. It is also first-line antiemetic prophylaxis, the standard for tumour-associated brain oedema and spinal cord compression, and a premedication for taxanes and pemetrexed. Hyperglycaemia, insomnia, myopathy, infection and adrenal suppression follow prolonged use.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-10
- Tags: nci-list; generic; supportive
- Brand: Decadron (historic) / Hemady / Neofordex
- Modality: Glucocorticoid
- Mechanism: Synthetic glucocorticoid receptor agonist; lympholytic in leukaemia, lymphoma and myeloma, anti-inflammatory and antiemetic through genomic and non-genomic actions.
- Approvals: US 1958: Palliative management of leukaemias and lymphomas; inflammatory and allergic conditions; US 2019: Multiple myeloma in combination with other antimyeloma products (Hemady); EU 2016: Multiple myeloma in combination (Neofordex)

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Dexamethasone
- US label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=dexamethasone
- NCI drug page: https://www.cancer.gov/about-cancer/treatment/drugs/dexamethasone
- EPAR (Neofordex): https://www.ema.europa.eu/en/medicines/human/EPAR/neofordex

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Acute promyelocytic leukaemia](https://onco.cc/cancers/apl/), [Adolescent and young adult cancers (ages 15 to 39)](https://onco.cc/cancers/aya-cancers/), [Advanced-stage classical Hodgkin lymphoma (stage III to IV)](https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/), [Brain metastases (secondary brain tumours)](https://onco.cc/cancers/secondary-brain-tumours/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Extranodal NK/T-cell lymphoma](https://onco.cc/cancers/extranodal-nk-t-cell-lymphoma/), [High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL)](https://onco.cc/cancers/all-paediatric-high-risk/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year)](https://onco.cc/cancers/all-infant/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Newly diagnosed multiple myeloma, transplant-eligible](https://onco.cc/cancers/myeloma-transplant-eligible/), [Newly diagnosed multiple myeloma, transplant-ineligible](https://onco.cc/cancers/myeloma-transplant-ineligible/), [Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL)](https://onco.cc/cancers/all-paediatric-ph-positive/), [Plasma cell leukaemia](https://onco.cc/cancers/plasma-cell-leukaemia/), [Relapsed and refractory acute lymphoblastic leukaemia in children](https://onco.cc/cancers/all-paediatric-relapsed/), [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/), [Smouldering multiple myeloma](https://onco.cc/cancers/smouldering-myeloma/), [Standard-risk B-cell acute lymphoblastic leukaemia in children](https://onco.cc/cancers/all-paediatric-standard-risk/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/), [Waldenström macroglobulinaemia](https://onco.cc/cancers/waldenstrom/)
- technologies: [Antiemetics for chemotherapy-induced nausea and vomiting](https://onco.cc/technologies/antiemetic-therapy/), [Bone after childhood cancer: peak bone mass, osteonecrosis and what rebuilds](https://onco.cc/technologies/rejuv-paed-bone/), [Memory, attention and learning after treatment of a childhood cancer](https://onco.cc/technologies/rejuv-paed-neurocognitive/), [Oral solid dose manufacturing (tablets and capsules)](https://onco.cc/technologies/oral-solid-dose-manufacturing/)
- terms: [Bone metastases and skeletal-related events](https://onco.cc/terms/bone-metastases/), [Cytokine release syndrome and ICANS: grading and management](https://onco.cc/terms/lymphoma-tx-crs-icans/), [Palliation in advanced triple-negative breast cancer: brain, bone, pleura, skin and end of life](https://onco.cc/terms/tnbc-symptom-control-palliation/), [The lymphoma regimen alphabet: R-CHOP, pola-R-CHP, DA-EPOCH-R, ABVD, BEACOPP and the rest](https://onco.cc/terms/lymphoma-tx-regimen-alphabet/)
- trials: [A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Darat](https://onco.cc/trials/nct04973605/), [A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)](https://onco.cc/trials/nct06464991/), [A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma](https://onco.cc/trials/nct06413498/), [A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Rela](https://onco.cc/trials/nct07391657/), [A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination Wi](https://onco.cc/trials/nct05455320/), [A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez](https://onco.cc/trials/nct06208150/), [A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With](https://onco.cc/trials/nct05572515/), [A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) ](https://onco.cc/trials/nct03539744/), [A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma](https://onco.cc/trials/nct05583617/), [A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethas](https://onco.cc/trials/nct06679101/), [A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractor](https://onco.cc/trials/nct03314181/), [A Study of Daratumumab](https://onco.cc/trials/nct05438043/), [A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Mul](https://onco.cc/trials/nct04133636/), [A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct02963493/), [A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide](https://onco.cc/trials/nct03151811/), [A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)](https://onco.cc/trials/nct06979596/), [A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Ly](https://onco.cc/trials/nct04442022/), [A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)](https://onco.cc/trials/nct03033511/), [A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refrac](https://onco.cc/trials/nct04414475/), [A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal](https://onco.cc/trials/nct05552222/), [A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)](https://onco.cc/trials/nct07742215/), [A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lena](https://onco.cc/trials/nct07095452/), [A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma ](https://onco.cc/trials/nct06953960/), [A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-spe](https://onco.cc/trials/nct06892522/), [A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple](https://onco.cc/trials/nct02773030/), [A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Tre](https://onco.cc/trials/nct03989414/), [A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatama](https://onco.cc/trials/nct06988488/), [A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)](https://onco.cc/trials/nct05319730/), [A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants W](https://onco.cc/trials/nct05552976/), [A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Re](https://onco.cc/trials/nct05519085/), [A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed ](https://onco.cc/trials/nct05372354/), [A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult](https://onco.cc/trials/nct07227311/), [A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Pl](https://onco.cc/trials/nct06824467/), [A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma](https://onco.cc/trials/nct07284758/), [A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types](https://onco.cc/trials/nct04300556/), [A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory](https://onco.cc/trials/nct05704049/), [A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatme](https://onco.cc/trials/nct05714839/), [A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide](https://onco.cc/trials/nct05623020/), [A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments](https://onco.cc/trials/nct05020236/), [A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell ](https://onco.cc/trials/nct06230224/), [A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Re](https://onco.cc/trials/nct05730036/), [AALL0232](https://onco.cc/trials/aall0232/), [AALL1231](https://onco.cc/trials/aall1231/), [Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemoth](https://onco.cc/trials/nct06616584/), [All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myelo](https://onco.cc/trials/nct06956170/), [ALL R3 (UKALLR3)](https://onco.cc/trials/ukallr3/), [Aplidin - Dexamethasone in Relapsed/Refractory Myeloma](https://onco.cc/trials/nct01102426/), [Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Gemcitabine Plus Paclitaxel](https://onco.cc/trials/nct07537660/), [Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Gemcitabine Combined With Paclitaxel Protein](https://onco.cc/trials/nct07716228/), [AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma](https://onco.cc/trials/nct06106945/), [CARTITUDE-6](https://onco.cc/trials/cartitude-6/), [CASSIOPEIA](https://onco.cc/trials/cassiopeia/), [Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer](https://onco.cc/trials/nct00024167/), [China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexame](https://onco.cc/trials/nct06868654/), [Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations](https://onco.cc/trials/nct02883049/), [Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia](https://onco.cc/trials/nct00557193/), [DETERMINATION](https://onco.cc/trials/determination/), [Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma](https://onco.cc/trials/nct00033332/), [Dexamethasone, Aspirin, and Diethylstilbestrol in Treating Patients With Locally Advanced or Metastatic Prostate Cancer](https://onco.cc/trials/nct00316927/), [Effect of Perioperative Lidocaine or High-Dose Dexamethasone on Immune Response in Colon Cancer Surgery (PILDI Study)](https://onco.cc/trials/nct07432399/), [FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutat](https://onco.cc/trials/nct05727163/), [High Dose Dexamethasone to Reduce Postoperative Pain After Video-Assisted Thoracoscopic Surgery Lobectomy /Segmentectomy](https://onco.cc/trials/nct07213375/), [IFM 2009](https://onco.cc/trials/ifm-2009/), [Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia](https://onco.cc/trials/nct03150693/), [International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia](https://onco.cc/trials/nct01117441/), [Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma](https://onco.cc/trials/nct04270409/), [Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dex](https://onco.cc/trials/nct06868667/), [LyMa](https://onco.cc/trials/lyma/), [MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other](https://onco.cc/trials/nct06152575/), [MAIA](https://onco.cc/trials/maia/), [Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants ](https://onco.cc/trials/nct04975997/), [PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarc](https://onco.cc/trials/nct05286814/), [Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)](https://onco.cc/trials/nct06788912/), [Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma](https://onco.cc/trials/nct07018050/), [Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple](https://onco.cc/trials/nct04126200/), [Premedication to Reduce Amivantamab Associated Infusion Related Reactions](https://onco.cc/trials/nct05663866/), [QUARTZ](https://onco.cc/trials/quartz/), [Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, A](https://onco.cc/trials/nct06305754/), [Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin](https://onco.cc/trials/nct03668639/), [Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)](https://onco.cc/trials/nct07387926/), [Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)](https://onco.cc/trials/nct06087653/), [Selinexor and Backbone Treatments of Multiple Myeloma Patients](https://onco.cc/trials/nct02343042/), [Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer](https://onco.cc/trials/nct04947189/), [SMILE](https://onco.cc/trials/smile-enktl/), [Study 3 (rolapitant, moderately emetogenic chemotherapy)](https://onco.cc/trials/ts-p04834/), [Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto](https://onco.cc/trials/nct06158841/), [Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)](https://onco.cc/trials/nct03061812/), [Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT](https://onco.cc/trials/nct07764978/), [Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma](https://onco.cc/trials/nct04649060/), [Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)](https://onco.cc/trials/nct02899052/), [Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies](https://onco.cc/trials/nct04068597/), [Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants Wi](https://onco.cc/trials/nct07150104/), [Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM](https://onco.cc/trials/nct07150091/), [Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)](https://onco.cc/trials/nct06353386/), [Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer](https://onco.cc/trials/nct05096663/), [Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma](https://onco.cc/trials/nct01700946/), [Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia](https://onco.cc/trials/nct00136084/), [Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer](https://onco.cc/trials/nct03367572/), [Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents](https://onco.cc/trials/nct03206671/)
- key papers: [AALL0232: dexamethasone and high-dose methotrexate improve outcome in high-risk B-cell acute lymphoblastic leukaemia in children and young adults](https://onco.cc/key-papers/paper-aall0232-larsen-jco-2016/), [CASSIOPEIA: daratumumab added to bortezomib, thalidomide and dexamethasone before and after transplant in newly diagnosed myeloma](https://onco.cc/key-papers/paper-cassiopeia-lancet-2019/), [IFM 2006 prospective trial: bortezomib-based induction and transplantation for primary plasma cell leukaemia](https://onco.cc/key-papers/paper-royer-plasma-cell-leukaemia-ifm-jco-2016/), [IFM 2009: lenalidomide, bortezomib and dexamethasone with or without upfront transplantation for myeloma](https://onco.cc/key-papers/paper-ifm-2009-attal-nejm-2017/), [Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study](https://onco.cc/key-papers/paper-smile-chemotherapy-nk-t-cell-lymphoma-jco-2011/), [QUARTZ: whole-brain radiotherapy versus supportive care alone for brain metastases from non-small-cell lung cancer](https://onco.cc/key-papers/paper-quartz-lancet-2016/), [Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma](https://onco.cc/key-papers/paper-lyma-rituximab-maintenance-after-transplant-mantle-cell-nejm-2017/)
- targets: [Glucocorticoid receptor (NR3C1)](https://onco.cc/targets/glucocorticoid-receptor/), [NK1 receptor (TACR1)](https://onco.cc/targets/tacr1/)
- drugs: [Aprepitant (and fosaprepitant)](https://onco.cc/drugs/aprepitant/), [Plitidepsin](https://onco.cc/drugs/plitidepsin/)
- companies: [Hikma Pharmaceuticals](https://onco.cc/companies/hikma/)

---
JSON: https://onco.cc/api/v1/entities/dexamethasone.json